Month: May 2021

Company Announcement No. 6-2021, 5 May 2021 Order intake increased for the third consecutive quarter Highlights in Q1 2021Order intake increased 6% compared to Q4 2020, and organic order intake decreased 19% y-o-y Organic revenue declined 13% y-o-y, comprising a 7% decrease in mining and a 23% decline in Cement EBITA margin increased slightly to 5.1%   Positive cash flow and reduction in net debt Cash focus and business improvement activities deliver results Continued reshaping of CementOrder intake increased for the third consecutive quarter, but decreased 19% organically y-o-y compared to the exceptionally strong Q1 2020. Including currency effects and acquisitions, order intake decreased by 24% y-o-y to DKK 4,985m. Sequentially, order intake increased 6% and service orders increased 19%. The order backlog increased by 9% to DKK...

 Financial report for the period 1 January 2021 to 31 March 2021Operating profit decreased by 8% in Danish kroner and increased by 3% at constant exchange rates (CER).  Sales remained unchanged in Danish kroner and increased by 7% at CER to DKK 33.8 billion. Sales in International Operations increased by 2% in Danish kroner (9% at CER), and sales in North America Operations decreased by 3% in Danish kroner (increased 6% at CER). Sales growth is negatively impacted by COVID-19-related stocking in 2020, partially offset by inventory changes and timing of shipments in 2021. Sales within Diabetes and Obesity care increased by 1% in Danish kroner to DKK 28.8 billion (9% at CER), driven by GLP-1 growth of 13% in Danish kroner (23% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Biopharm sales decreased by 6% in Danish kroner (increased...

TORONTO, May 05, 2021 (GLOBE NEWSWIRE) — International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operating results and related management’s discussion and analysis (MD&A) for the three months ended March 31, 2021. Q1 2021 Financial and Operational HighlightsAverage net production of approximately 43,700 barrels of oil equivalent (boe) per day (boepd) for the first quarter of 2021 (44% heavy crude oil, 19% light and medium crude oil and 37% natural gas)(1). Average net production is above the high end of the 2021 Capital Markets Day (CMD) guidance range for the first quarter of 2021, with exceptional operational performance and high uptimes recorded across IPC’s portfolio. Full year 2021 average net production is expected to be towards the high end of the...

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operating results and related management’s discussion and analysis (MD&A) for the three months ended March 31, 2021. Q1 2021 Financial and Operational HighlightsAverage net production of approximately 43,700 barrels of oil equivalent (boe) per day (boepd) for the first quarter of 2021 (44% heavy crude oil, 19% light and medium crude oil and 37% natural gas)(1). Average net production is above the high end of the 2021 Capital Markets Day (CMD) guidance range for the first quarter of 2021, with exceptional operational performance and high uptimes recorded across IPC’s portfolio. Full year 2021 average net production is expected to be towards the high end of the forecast 41,000 to 43,000 boepd range(1). Operating...

ABERDEEN, United Kingdom, May 05, 2021 (GLOBE NEWSWIRE) — Altera Infrastructure GP LLC (Altera GP), the general partner of Altera Infrastructure L.P. (Altera or the Partnership), today reported the Partnership’s results for the quarter ended March 31, 2021.Revenues of $272.8 million and net income of $5.9 million, or $0.00 per common unit, in the first quarter of 2021 Adjusted EBITDA(1) of $120.3 million in the first quarter of 2021The following table presents the Partnership’s Consolidated Financial Summary:    Three Months Ended    March 31,   December 31,   March 31,  2021   2020    2020 In thousands of U.S. Dollars, unaudited $   $   $IFRS FINANCIAL RESULTS          Revenues 272,754   278,657     312,401  Net Income (loss) 5,901   (73,029 )   (258.932 )Limited partners’ interest in net...

MONT-SAINT-GUIBERT, Belgium, May 05, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification from Tolefi SA, dated 3 May 2021. Tolefi SA has notified that its 2.295.701 shares benefit from a double voting right as of May 3, 2021 and that its shareholding has crossed above the threshold of 25%. The full transparency notice is available on the Celyad website under the heading “Regulated Information”. About Celyad Oncology SA Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is...

Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study Tecentriq approval offers an alternative to chemotherapy for all eligible patients This approval marks Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EUBasel, 5 May 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. “We are delighted to bring Tecentriq to people in the EU with this specific type of lung...

Strong cash and cash equivalents position at March 31, 2021 of CHF25.2M ($26.7M) Completed $11.5M fundraising in January 2021 Three clinical studies in neurology programs remain on track to start during Q2 2021 Neurology programs aimed at large underserved market opportunities in dyskinesia associated with Parkinson’s disease, blepharospasm and epilepsyGeneva, Switzerland, May 5, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the quarter ended March 31, 2021 and provided a corporate update. “We are on track with clinical studies planned to begin this quarter, including two internal dipraglurant programs in dyskinesia associated with Parkinson’s disease and blepharospasm, as well...

Uponor Corporation     Stock exchange release     5 May 2021     08:00 EET Interim report January–March 2021: Strong demand in building solutions in Europe and North America drive the increase in comparable operating profit January-March 2021Net sales in January–March totalled €309.2 (277.4) million, a growth of 11.4%. Organic growth was 14.4% in constant currency terms. Comparable operating profit was €47.6 (29.5) million, a growth of 61.5%. Operating profit was €47.0 (28.6) million, a growth of 64.4%. Earnings per share were €0.43 (0.30). Return on investment was 29.6% (21.4) and gearing 9.2% (52.2). Cash flow from business operations was €6.1 (-11.3) million.Guidance statement for 2021: Updated on 16 April 2021: Excluding the impact of currencies, Uponor expects its net sales to increase from year 2020 and its comparable operating...

Register now to the webcast scheduled at 15:00 CESTLink to financial report Solvay first quarter 2021 resultsStrong start to the year with double-digit growth in Cash and EBITDA and record EBITDA margins May 5, 2021 at 7 a.m. CEST  HighlightsNet Sales in the first quarter of 2021 were up 1.9% organically driven by strong demand in automotive, with organic sales in Specialty Polymers up 10% year-on-year, exceptional performance in Coatis up 55%, and recovery in the mining industry driving Technology Solutions sales up 15%, whereas sales in Composites were 37% lower. Net Sales grew 8.6% organically year on year excluding Composites and Oil & Gas, which still face challenges yet have shown sequential improvement versus the fourth quarter. Structural cost savings of €80 million achieved in Q1, up 78% versus Q4 2020. Underlying EBITDA...